Analysts have set 12-month price targets for Eton Pharmaceuticals, revealing an average target of $24.4, a high estimate of $33.00, and a low estimate of $17.00. Marking an increase of 22.0%, the ...

Q4 2024 Earnings Call Transcript March 18, 2025 Eton Pharmaceuticals, Inc. reports earnings inline with expectations.

Management to Hold Investor Day Conference Call Today at 10:00am ETReported record product revenue of $11.6 million in Q4 2024, an increase of ...

Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.09 per share a year ago. These figures are ...

Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 8.4% growth forecast ...

ETON PHARMACEUTICALS ($ETON) posted quarterly earnings results on Tuesday, March 18th. The company reported earnings of -$0.02 per share, missing estimates of -$0.00 ...

Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study -- Company expects to submit New Drug ...

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce ...

Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients –– $0 co-pay for all eligible patients and best-in-class patient support services ...

We want to build a large leading ultra-rare disease company that brings as many new treatments to patients as possible. We intend to do that by putting patients first. Eton operates on the ...

Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq ...